Revelation Biosciences Inc
REVB
NASDAQ
Biotechnology
$1.05
USD
-0.06 (-5.50%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $4.42M
Volume 31.2K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-10.75M
TTM
-27.0%
YoY
Operating Cash Flow
$-9.33M
TTM
+47.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 1.1 | 1.0 | 1.6 | 1.7 | 1.7 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 2.5 | 1.9 | 2.6 | 3.1 | 3.7 |
Operating Income | -2.5 | -1.9 | -2.6 | -3.1 | -3.7 |
EBITDA | -2.5 | -1.9 | -2.6 | -3.1 | -3.7 |
Other Income / Expense | 0.0 | 0.0 | 0.1 | 0.1 | 0.3 |
Total Other Income / Expense | 0.0 | 0.0 | 0.1 | 0.1 | 0.3 |
Income Before Income Taxes | -2.4 | -1.9 | -2.5 | -3.0 | -3.3 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -2.4 | -1.9 | -2.5 | -3.0 | -3.3 |
Consolidated Net Income / Loss | -2.4 | -1.9 | -2.5 | -3.0 | -3.3 |
Net Income Attributable to Common Shareholders | -5.6 | -4.7 | -2.5 | -8.7 | -3.3 |
Basic EPS | -$28.04 | -$7.08 | -$1.63 | -$2.71 | -$0.87 |
Diluted EPS | -$28.04 | -$7.08 | -$1.63 | -$2.71 | -$0.87 |
Basic Shares Outstanding | 0.2M | 0.7M | 1.5M | 3.2M | 3.8M |
Diluted Shares Outstanding | 0.2M | 0.7M | 1.5M | 3.2M | 3.8M |